San Diego Biotech Seawolf Secures $1.2B Sanofi Alliance as Coastal High Surf Warnings Batter Shorelines

G
Grace
Nov 16, 2026 San Diego

San Diego Biotech Startup Seawolf Therapeutics Launches with $100M Series A and $1.2B Sanofi Deal

SAN DIEGO, California — Cementing San Diego's reputation as a world-leading life sciences capital, biotech startup Seawolf Therapeutics emerged from stealth on Monday, November 16, 2026, announcing $100 million in Series A funding and an exclusive research collaboration with Sanofi valued at up to $1.2 billion. The company’s innovative synthetic biology platform engineers non-viral, redosable DNA therapeutics designed to treat severe genetic illnesses without eliciting adverse neutralizing antibody responses.

Cardiff Oncology Receives FDA Fast Track Designation for Colorectal Cancer Therapy

Adding to local biotech momentum, San Diego-based Cardiff Oncology announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead compound *onvansertib* in combination with standard frontline regimens for RAS-mutated metastatic colorectal cancer, expediting regulatory review for patients with limited therapeutic options.

Powerful Open-Ocean Pacific Swells Produce 10-Foot Breakers Along San Diego Shorelines

Energetic winter swells fueled by North Pacific storm tracks generated breaker heights exceeding 10 feet across iconic San Diego surf breaks from Ocean Beach to Torrey Pines on Sunday and Monday. San Diego Fire-Rescue lifeguards placed warning buoys and manned coastal rescue vessels to safeguard beachgoers against treacherous rip currents and localized tidal surge.